Investigators at Case Western Reserve University School of Medicine received a $6.75 million Program Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study the role of innate immunity in inflammatory bowel disease (IBD)…
More: continued here
Filed under: Irritable-Bowel Syndrome on December 22nd, 2011 | No Comments »
Summary: A vascular condition called chronic cerebrospinal venous insufficiency (CCSVI), which has attracted global attention as possibly being correlated with MS has, for the first time, been studied for the presence of risk factors in subjects who do not have a neurological disease…
More: continued here
Filed under: Irritable-Bowel Syndrome on December 2nd, 2011 | No Comments »
Among the most commonly used treatments for irritable bowel syndrome which affects as many as 20 percent of the United States population a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials. The study, for presentation at the American College […]
Filed under: Irritable-Bowel Syndrome on November 6th, 2011 | No Comments »
The intestinal ecosystem is even more dynamic than previously thought, according to two studies by UT Southwestern Medical Center researchers published in the latest issue of Science…
More: continued here
Filed under: Irritable-Bowel Syndrome on October 20th, 2011 | No Comments »
Neuroticism - the tendency to experience negative emotions - significantly affects brain processing during pain, as well as during the anticipation of pain, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association…
More: continued here
Filed under: Irritable-Bowel Syndrome on September 21st, 2011 | No Comments »
Tioga Pharmaceuticals, Inc. announced that its investigational compound asimadoline has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS)…
More: continued here
Filed under: Irritable-Bowel Syndrome on June 2nd, 2011 | No Comments »
Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness…
More: continued here
Filed under: Irritable-Bowel Syndrome on April 22nd, 2011 | No Comments »
The study, which was conducted at Sahlgrenska University Hospital in Gothenburg and at Alingsas Hospital, included 102 IBS patients between the ages of 18 and 65. Half the group was randomly allocated to increase their physical activity and the other half to maintain their usual lifestyle. Both groups received supportive phone calls from a physiotherapist…
More: […]
Filed under: Irritable-Bowel Syndrome on January 30th, 2011 | No Comments »
Altheus Therapeutics, Inc., announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa? Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis. No serious adverse events were experienced by patients in this study…
More: continued here
Filed under: Irritable-Bowel Syndrome on January 11th, 2011 | No Comments »
Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease (IBD)…
More: continued here
Filed under: Irritable-Bowel Syndrome on January 11th, 2011 | No Comments »